Zhang Mingzhou, Tang Ting, Wan Min, Zhang Qiao, Wang Changzheng, Ma Qianli
Institute of Respiratory Disease, Xinqiao Hospital, Third Military Medical University, Chongqing, China.
Ann Palliat Med. 2020 Sep;9(5):3495-3505. doi: 10.21037/apm-20-1741.
Adherence to medication plays an important role in the control of disease progression and treatment costs for patients with chronic obstructive pulmonary disease (COPD). Existing studies are mostly retrospective studies based on local medical insurance databases and prescription records and therefore cannot analyze or determine the causes of poor adherence in COPD patients.
This is a prospective study that enrolled 1,223 COPD patients, including 929 newly diagnosed patients and 294 previously diagnosed patients. Telephone follow-up was conducted to administer a questionnaire on treatment adherence and collect detailed information on the prescriptions and the actual use of medications for COPD. The follow-up period was 24 weeks.
COPD patients had adherence rates of 74.65%, 49.63%, and 33.61% at 4-, 12-, and 24-week telephone follow-ups, respectively. Cox regression showed that women, newly diagnosed patients, patients with a mild Global Initiative for Chronic Obstructive Lung Disease (GOLD) stage, and patients with fewer routes of administration had poorer adherence. According to the subgroup analysis of the diagnostic status, the overall adherence of the newly diagnosed patients was poorer than that of the previously diagnosed patients. Among the causes of nonadherence, drug stoppage after remission (27.2%) was the most common cause, followed by economic factors (21.5%) and poor efficacy (21.1%).
This is the first study focusing on the adherence behavior of newly diagnosed COPD patients and the first large-scale clinical study on the Chinese population. Overall, sex, diagnostic status (newly diagnosed and previously diagnosed), GOLD stage, and routes of administration were the four major factors that affected the adherence of COPD patients.
坚持用药对慢性阻塞性肺疾病(COPD)患者的疾病进展控制和治疗费用起着重要作用。现有研究大多是基于当地医疗保险数据库和处方记录的回顾性研究,因此无法分析或确定COPD患者依从性差的原因。
这是一项前瞻性研究,纳入了1223例COPD患者,其中包括929例新诊断患者和294例既往诊断患者。通过电话随访进行治疗依从性问卷调查,并收集COPD处方及药物实际使用情况的详细信息。随访期为24周。
在4周、12周和24周的电话随访中,COPD患者的依从率分别为74.65%、49.63%和33.61%。Cox回归分析显示,女性、新诊断患者、慢性阻塞性肺疾病全球倡议(GOLD)轻度分期患者以及给药途径较少的患者依从性较差。根据诊断状态的亚组分析,新诊断患者的总体依从性低于既往诊断患者。在不依从的原因中,缓解后停药(27.2%)是最常见的原因,其次是经济因素(21.5%)和疗效不佳(21.1%)。
这是第一项关注新诊断COPD患者依从行为的研究,也是第一项针对中国人群的大规模临床研究。总体而言,性别、诊断状态(新诊断和既往诊断)、GOLD分期和给药途径是影响COPD患者依从性的四个主要因素。